Clinical strategy reviewed by Clinical Advisory Board
Rejuvenate Biomed organized its first Clinical Advisory Board meeting to evaluate the clinical development plan for RJx-01 as a safe therapeutic to treat sarcopenia.
Key research collaboration with Prof. Rafael de Cabo
Rejuvenate Biomed collaborates under a CRADA with Dr. Rafael de Cabo, MD, PhD, Professor at the NIA`s Translational Gerontology Branch.
VLAIO funding (Baekeland mandate)
Rejuvenate Biomed supports Sven Bulterijs in his PhD under guidance of Prof. Bart Braeckman at Ghent University. His work will focus on C. elegans research in the context of aging.
Strategic partnership with PhaRA Consulting to navigate the regulatory pathways
As a partner, PhaRA Consulting will use their regulatory affairs expertise to support Rejuvenate Biomed’s clinical and commercial objectives.
VLAIO funding €1.16 million euro to facilitate research
Rejuvenate Biomed has been awarded a €1,160,000 grant from VLAIO to accelerate drug development for healthy aging.